Showing 4111-4120 of 5911 results for "".
- Baxter Launches Digital Image Capture Capability of Panoptic Plus Ophthalmoscopehttps://modernod.com/news/baxter-launches-digital-image-capture-capability-of-panoptic-plus-ophthalmoscope/2481891/Baxter International announced the launch of digital image capture capability for eye exams using its existing Welch Allyn PanOptic Plus Ophthalmoscope. The iExaminer Pro System adds a key technology to routine eye exams, designed to help advance healthcare professio
- Tilak Healthcare Raises €10 Million to Continue Growing Its Ophthalmological Telemedicine Offeringhttps://modernod.com/news/tilak-healthcare-raises-eur10-million-to-continue-growing-its-leading-ophthalmological-telemedicine-offering/2481890/Tilak Healthcare has raised €10 million in a funding to accelerate the roll-out of OdySight in France and abroad, and to develop new solutions for other medical conditions. OdySight is the first remote monitoring system for ophthalmic conditions combined with a gaming interface designed
- Heidelberg Engineering Receives FDA Clearance for Anterion Platformhttps://modernod.com/news/heidelberg-engineering-announces-fda-clearance-of-anterion-platform/2481889/Heidelberg Engineering has received FDA clearance of its Anterion platform, designed to improve anterior segment diagnostics and streamline practice workflow. “Building upon our previous CE-marking, we are thrilled that the Anterion platform is
- Sight Sciences Presents Phase 1 Results of the SAHARA Trial Comparing TearCare to Restasis for the Treatment of Dry Eye Diseasehttps://modernod.com/news/sight-sciences-presents-phase-1-results-of-the-sahara-trial-comparing-tearcare-to-restasis-for-the-treatment-of-dry-eye-disease/2481888/Sight Sciences announced the presentation of the full phase 1 results from the SAHARA randomized controlled trial, demonstrating that interventional eyelid procedures for dry eye disease enabled by TearCare technology were superior at all measured time points to Restasis prescription eye dro
- OKYO Pharma Announces Filing of an IND Application for OK-101 to Treat Neuropathic Corneal Painhttps://modernod.com/news/okyo-pharma-announces-filing-of-an-ind-application-for-ok-101-to-treat-neuropathic-corneal-pain/2481882/OKYO Pharma announced that it filed an investigational new drug (IND) application with the FDA for the development of OK-101 to treat Neuropathic Corneal Pain (NCP). Study enrollment is planned to commence during Q1 2024 following IND allowance by the FDA. There is no FDA-appr
- Two-Year Results of Eylea HD (Aflibercept 8 mg) from PULSAR Trial for Wet AMD Presented at Euretinahttps://modernod.com/news/two-year-results-of-eylea-hd-aflibercept-8-mg-from-pulsar-trial-presented-at-euretina/2481870/Regeneron announced the first presentation of positive 2-year (96 weeks) results from the PULSAR trial investigating Eylea HD (aflibercept) injection 8 mg with 12- and 16-week dosing regimens, compared to Eylea (aflibercept) injection, in patients with wet age-related macular degenerati
- Bausch + Lomb Launches New Range of Pure‐Line Gases at Euretinahttps://modernod.com/news/bausch-lomb-launches-new-range-of-pureline-gases-at-euretina-1/2481869/Bausch + Lomb announced the European launch of the new range of Pure‐line gases during the European Society of Retina Specialists (Euretina) annual meeting, taking place in Amsterdam, The Netherlands, Oct. 5‐ 8, 2023. Designed for ease of use, the Pure‐line gases are available as both p
- Resolving a Seeming Contradiction, Study Advances Understanding of Visual Recognition Memoryhttps://modernod.com/news/resolving-a-seeming-contradiction-study-advances-understanding-of-visual-recognition-memory/2481866/Researchers from The Picower Institute for Learning and Memory have published a study evaluating how our vision is so good at recognizing what’s familiar. The study, published in the Journa
- Humonix Biosciences Launches 3D Human Tissue Modelhttps://modernod.com/news/specialty-pharmaceutical-research-company-humonix-biosciences-launches-3d-human-tissue-model/2481864/Humonix Biosciences has developed a new 3D human tissue model called the retinal vascular dysfunction model. Humonix’s new model is a physiologically relevant 3D model of the blood-retinal barrier. This model expresses key physiological and biological characteristics, providing a platf
- Nanoscope Therapeutics Announces Presentations at Upcoming Conferenceshttps://modernod.com/news/nanoscope-therapeutics-announces-presentations-at-upcoming-conferences/2481862/Nanoscope Therapeutics, which is developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), is scheduled to participate in the 2023 Ophthalmology Futures Retina Forum and Euretina Innovation Spotlight at the 23rd Euretina Congress, each taking place